1. Insights into DNMT1 and programmed cell death in diseases
   Lan Yan et al, 2023, Biomedicine & Pharmacotherapy CrossRef
2. 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential
   Karolina Łuczkowska et al, 2023, International Journal of Molecular Sciences CrossRef
3. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
   Marta Pelon et al, 2024, Frontiers in Pharmacology CrossRef
4. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
   Catharina Muylaert et al, 2022, Frontiers in Oncology CrossRef
5. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
   Sara Ovejero et al, 2021, Exploration of Targeted Anti-tumor Therapy CrossRef
6. Decoding DNA methylation in epigenetics of multiple myeloma
   Ting Yang et al, 2022, Blood Reviews CrossRef
7. Synergistic inhibitory effects of low‑dose decitabine in combination with bortezomib in the AML cell line Kasumi‑1
   Vassiliki Mpakou et al, 2021, Experimental and Therapeutic Medicine CrossRef
8. Proteasome Inhibitors with a Focus on Bortezomib
   Kevin Barley et al, 2018, Resistance of Targeted Therapies Excluding Antibodies for Lymphomas CrossRef
9. The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
   Eva De Smedt et al, 2018, Frontiers in Oncology CrossRef
10. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Sara Ovejero et al, 2021, Exploration of Targeted Anti-tumor Therapy CrossRef
11. Protein-Functionalized Microgel for Multiple Myeloma Cells’ 3D Culture
    Juan Carlos Marín-Payá et al, 2022, Biomedicines CrossRef
12. Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient
    Pasquale Niscola et al, 2018, Acta Haematologica CrossRef
13. Regulatory mechanisms of B cell responses and the implication in B cell-related diseases
    Dong-Yan Tsai et al, 2019, Journal of Biomedical Science CrossRef
14. The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
    Tina Paradzik et al, 2021, Cancers CrossRef
15. Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action
    Piotr Kulig et al, 2023, Cancers CrossRef
16. Addition of low‐dose decitabine to bortezomib and dexamethasone as second‐line therapy in multiple myeloma
    Ning Li et al, 2020, British Journal of Haematology CrossRef
17. Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression
    Patryk Krzeminski et al, 2020, Cellular Oncology CrossRef
18. Biomimetic 3D Environment Based on Microgels as a Model for the Generation of Drug Resistance in Multiple Myeloma
    Juan Carlos Marín-Payá et al, 2021, Materials CrossRef